HER2-negative breast cancers show 17q12 deletion and ERBB2 loss

A recent paper by X. Qiu et al. was mentioned by Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, on X:

“Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2”

Authors: X. Qiu et al.

“Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2.

• ERBB2 mRNA levels are associated with significant variations in mutational landscapes and transcriptional profiles.
• 17q12del with heterozygous loss of ERBB2 is a biologically distinct subgroup of BCs with very low HER2 expression levels.
• Metastatic BCs with a 17q12del with heterozygous loss of ERBB2 have worse OS.”

More posts featuring Elisabetta Bonzano.